{"symbol": "ABBV", "publishedDate": "2022-01-19 06:00:09", "publisher": "InvestorPlace", "title": "3 Dividend Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/3-dividend-stocks-to-buy-and-hold-forever-20220119.jpg", "site": "investorplace.com", "text": "Investors wanting dividends to fortify their portfolio should consider dividend stocks that deliver outsized payments to shareholders. The post 3 Dividend Stocks to Buy and Hold Forever appeared first on InvestorPlace.", "url": "https://investorplace.com/2022/01/3-dividend-stocks-to-buy-and-hold-forever-abbv-kr-cvx/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-19T06:00:09-05:00", "date_et": "2022-01-19"}
{"symbol": "ABBV", "publishedDate": "2022-01-19 11:54:28", "publisher": "InvestorPlace", "title": "3 Healthcare Stocks Ignoring the Market Mayhem", "image": "https://images.financialmodelingprep.com/news/3-healthcare-stocks-ignoring-the-market-mayhem-20220119.jpg", "site": "investorplace.com", "text": "Sellers dominate the Street this week, but some healthcare stocks remain unaffected. Here are three to put atop your watchlist.", "url": "https://investorplace.com/2022/01/3-healthcare-stocks-ignoring-the-market-mayhem/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-19T11:54:28-05:00", "date_et": "2022-01-19"}
{"symbol": "ABBV", "publishedDate": "2022-01-20 14:29:04", "publisher": "InvestorPlace", "title": "3 Dividend Aristocrats Yielding Over 4%", "image": "https://images.financialmodelingprep.com/news/3-dividend-aristocrats-yielding-over-4-20220120.jpg", "site": "investorplace.com", "text": "When looking for great dividend stocks, one of the best places to start is with the Dividend Aristocrats. These companies have stood the test of time and economic weakness, and in the case of Leggett & Platt, AbbVie and Chevron, they all have current yields that are more than triple that of the S&P 500.", "url": "https://investorplace.com/2022/01/3-dividend-aristocrats-yielding-over-4/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-20T14:29:04-05:00", "date_et": "2022-01-20"}
{"symbol": "ABBV", "publishedDate": "2022-01-20 14:35:08", "publisher": "Zacks Investment Research", "title": "3 Value Stocks Breaking out in 2022", "image": "https://images.financialmodelingprep.com/news/3-value-stocks-breaking-out-in-2022-20220120.jpg", "site": "zacks.com", "text": "Not all stocks are selling off to start 2022. These cheap, top Zacks Ranked stocks are doing the opposite.", "url": "https://www.zacks.com/stock/news/1854841/3-value-stocks-breaking-out-in-2022", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-20T14:35:08-05:00", "date_et": "2022-01-20"}
{"symbol": "ABBV", "publishedDate": "2022-01-20 22:07:39", "publisher": "Stockmarket.com", "title": "Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist", "image": "https://images.financialmodelingprep.com/news/top-biotech-stocks-to-buy-now-5-for-your-20220120.jpg", "site": "stockmarket.com", "text": "Which biotech stocks are you watching today?", "url": "https://stockmarket.com/featured/top-biotech-stocks-to-buy-now-5-for-your-late-january-watchlist-2022-01-20", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-20T22:07:39-05:00", "date_et": "2022-01-20"}
{"symbol": "ABBV", "publishedDate": "2022-01-21 16:30:00", "publisher": "PRNewsWire", "title": "U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis", "image": "https://images.financialmodelingprep.com/news/us-fda-approves-second-indication-for-skyrizi-risankizumabrzaa-to-20220121.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., Jan. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.1,4-7 The FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy and safety of SKYRIZI in adults with active PsA, including those who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying antirheumatic drugs (DMARDs).2,3 Across the two Phase 3 studies, SKYRIZI met the primary endpoint of ACR20 response at week 24 compared to placebo and demonstrated significant improvements across several other manifestations of PsA, including swollen, tender and painful joints.2,3 \"Patients often do not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness they may be experiencing, potentially leading to a delay in diagnosis and treatment of psoriatic arthritis,\" said Thomas Hudson, M.D.", "url": "https://www.prnewswire.com/news-releases/us-fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-active-psoriatic-arthritis-301466021.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-21T16:30:00-05:00", "date_et": "2022-01-21"}
{"symbol": "ABBV", "publishedDate": "2022-01-22 09:30:00", "publisher": "The Motley Fool", "title": "1 Top Dividend Stock to Buy Right Now", "image": "https://images.financialmodelingprep.com/news/1-top-dividend-stock-to-buy-right-now-20220122.jpg", "site": "fool.com", "text": "Dividends can provide a safe harbor in the market storm.", "url": "https://www.fool.com/investing/2022/01/22/1-top-dividend-stock-to-buy-right-now/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-22T09:30:00-05:00", "date_et": "2022-01-22"}
{"symbol": "ABBV", "publishedDate": "2022-01-23 06:12:00", "publisher": "The Motley Fool", "title": "Is AbbVie Stock a Top Pick for 2022?", "image": "https://images.financialmodelingprep.com/news/is-abbvie-stock-a-top-pick-for-2022-20220123.jpg", "site": "fool.com", "text": "Can this high-yielder help shore up your portfolio in an unstable market?", "url": "https://www.fool.com/investing/2022/01/23/is-abbvie-stock-a-top-pick-for-2022/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-23T06:12:00-05:00", "date_et": "2022-01-23"}
{"symbol": "ABBV", "publishedDate": "2022-01-24 06:10:00", "publisher": "The Motley Fool", "title": "These High-Yield Dividend Stocks Are Growing at Blazing Speeds", "image": "https://images.financialmodelingprep.com/news/these-highyield-dividend-stocks-are-growing-at-blazing-speeds-20220124.jpg", "site": "fool.com", "text": "Investors willing to venture a little off the beaten path will find income and growth don't have to be mutually exclusive.", "url": "https://www.fool.com/investing/2022/01/24/these-high-yield-dividend-stocks-are-growing-at-bl/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-24T06:10:00-05:00", "date_et": "2022-01-24"}
{"symbol": "ABBV", "publishedDate": "2022-01-24 08:00:00", "publisher": "The Motley Fool", "title": "3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150", "image": "https://images.financialmodelingprep.com/news/3-nobrainer-healthcare-stocks-to-buy-right-now-for-20220124.jpg", "site": "fool.com", "text": "Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend.", "url": "https://www.fool.com/investing/2022/01/24/3-no-brainer-healthcare-stocks-to-buy-right-now-fo/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-24T08:00:00-05:00", "date_et": "2022-01-24"}
{"symbol": "ABBV", "publishedDate": "2022-01-24 08:00:00", "publisher": "PRNewsWire", "title": "Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)", "image": "https://images.financialmodelingprep.com/news/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic-20220124.jpg", "site": "prnewswire.com", "text": "IRVINE, Calif., Jan. 24, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX® Cosmetic Story.", "url": "https://www.prnewswire.com/news-releases/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic-onabotulinumtoxina-301466077.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-24T08:00:00-05:00", "date_et": "2022-01-24"}
{"symbol": "ABBV", "publishedDate": "2022-01-24 10:49:06", "publisher": "Zacks Investment Research", "title": "AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis", "image": "https://images.financialmodelingprep.com/news/abbvies-abbv-skyrizi-gets-fda-nod-for-psoriatic-arthritis-20220124.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.", "url": "https://www.zacks.com/stock/news/1856107/abbvie-s-abbv-skyrizi-gets-fda-nod-for-psoriatic-arthritis", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-24T10:49:06-05:00", "date_et": "2022-01-24"}
{"symbol": "ABBV", "publishedDate": "2022-01-24 19:14:49", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Gains But Lags Market: What You Should Know", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-gains-but-lags-market-what-you-should-20220124.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) closed at $132.16 in the latest trading session, marking a +0.14% move from the prior day.", "url": "https://www.zacks.com/stock/news/1856415/abbvie-abbv-gains-but-lags-market-what-you-should-know", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-24T19:14:49-05:00", "date_et": "2022-01-24"}
{"symbol": "ABBV", "publishedDate": "2022-01-25 12:56:31", "publisher": "Seeking Alpha", "title": "Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon", "image": "https://images.financialmodelingprep.com/news/vertex-investors-look-outabbvie-data-in-cystic-fibrosis-coming-20220125.jpg", "site": "seekingalpha.com", "text": "Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon", "url": "https://seekingalpha.com/article/4481482-vertex-investors-look-out-abbv-data-coming-soon", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-25T12:56:31-05:00", "date_et": "2022-01-25"}
{"symbol": "ABBV", "publishedDate": "2022-01-25 13:32:04", "publisher": "Seeking Alpha", "title": "AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent Loss", "image": "https://images.financialmodelingprep.com/news/abbvie-skyrizi-and-rinvoq-latest-fda-approvals-bode-well-20220125.jpg", "site": "seekingalpha.com", "text": "Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, which was approved for the treatment of adults and children ages 12 and older for moderate to severe atopic dermatitis.", "url": "https://seekingalpha.com/article/4481505-abbvie-skyrizis-and-rinvoq-latest-fda-approvals-bode-well-for-humira-patent-loss", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-25T13:32:04-05:00", "date_et": "2022-01-25"}
{"symbol": "ABBV", "publishedDate": "2022-01-26 10:45:00", "publisher": "The Motley Fool", "title": "2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell", "image": "https://images.financialmodelingprep.com/news/2-reasons-to-buy-abbvie-stock-and-1-reason-20220126.jpg", "site": "fool.com", "text": "This stock has a lot in its favor, but there's also a big near-term risk.", "url": "https://www.fool.com/investing/2022/01/26/2-reasons-to-buy-abbvie-stock-and-1-reason-to-sell/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-26T10:45:00-05:00", "date_et": "2022-01-26"}
{"symbol": "ABBV", "publishedDate": "2022-01-26 16:24:46", "publisher": "Seeking Alpha", "title": "LABU - A Compelling Biotech Trade", "image": "https://images.financialmodelingprep.com/news/labu-a-compelling-biotech-trade-20220126.jpg", "site": "seekingalpha.com", "text": "LABU - A Compelling Biotech Trade", "url": "https://seekingalpha.com/article/4481870-labu-a-compelling-biotech-trade", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-26T16:24:46-05:00", "date_et": "2022-01-26"}
{"symbol": "ABBV", "publishedDate": "2022-01-27 10:46:15", "publisher": "Zacks Investment Research", "title": "Should Value Investors Pick AbbVie (ABBV) At Present?", "image": "https://images.financialmodelingprep.com/news/should-value-investors-pick-abbvie-abbv-at-present-20220127.jpg", "site": "zacks.com", "text": "Is AbbVie (ABBV) a great pick from the value investor's perspective right now? Read on to know more.", "url": "https://www.zacks.com/stock/news/1858178/should-value-investors-pick-abbvie-abbv-at-present", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-27T10:46:15-05:00", "date_et": "2022-01-27"}
{"symbol": "ABBV", "publishedDate": "2022-01-27 13:50:10", "publisher": "Zacks Investment Research", "title": "2 Stocks to Buy During Market Turbulence Before Earnings", "image": "https://images.financialmodelingprep.com/news/2-stocks-to-buy-during-market-turbulence-before-earnings-20220127.jpg", "site": "zacks.com", "text": "Diving into two strong stocks that also pay a dividend that investors might want to consider buying heading into earnings.", "url": "https://www.zacks.com/stock/news/1858443/2-stocks-to-buy-during-market-turbulence-before-earnings", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-27T13:50:10-05:00", "date_et": "2022-01-27"}
{"symbol": "ABBV", "publishedDate": "2022-01-28 12:19:30", "publisher": "Zacks Investment Research", "title": "Is a Beat Likely for AbbVie (ABBV) This Earnings Season?", "image": "https://images.financialmodelingprep.com/news/is-a-beat-likely-for-abbvie-abbv-this-earnings-20220128.jpg", "site": "zacks.com", "text": "AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022.", "url": "https://www.zacks.com/stock/news/1859098/is-a-beat-likely-for-abbvie-abbv-this-earnings-season", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-28T12:19:30-05:00", "date_et": "2022-01-28"}
{"symbol": "ABBV", "publishedDate": "2022-01-28 16:09:19", "publisher": "Zacks Investment Research", "title": "Value, Growth, or Momentum: What Kind of Investor are You?", "image": "https://images.financialmodelingprep.com/news/value-growth-or-momentum-what-kind-of-investor-are-20220128.jpg", "site": "zacks.com", "text": "No matter what strategy you decide is best in 2022, always remember that investing is a personal journey. Your life, and where you see yourself in 10, 20, 30 years, should be the driving force behind your investing decisions and strategies.", "url": "https://www.zacks.com/commentary/1859303/value-growth-or-momentum-what-kind-of-investor-are-you", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-28T16:09:19-05:00", "date_et": "2022-01-28"}
{"symbol": "ABBV", "publishedDate": "2022-01-28 17:04:55", "publisher": "Invezz", "title": "Mizuho's Vamil Divan reveals his top biotech pick", "image": "https://images.financialmodelingprep.com/news/mizuhos-vamil-divan-reveals-his-top-biotech-pick-20220128.jpg", "site": "invezz.com", "text": "AbbVie Inc (NYSE: ABBV) closed 2021 with a 25% gain in the stock price, and Mizuho's senior biopharmaceuticals research analyst says 2022 will be another year of outperformance for the biotech giant. Divan sees upside to $154 a share According to Vamil Divan, AbbVie is his top biotech pick, which he rates at “buy” with […] La notizia Mizuho's Vamil Divan reveals his top biotech pick era stato segnalata su Invezz.", "url": "https://invezz.com/news/2022/01/28/mizuhos-vamil-divan-reveals-his-top-biotech-pick/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-28T17:04:55-05:00", "date_et": "2022-01-28"}
{"symbol": "ABBV", "publishedDate": "2022-01-29 05:58:00", "publisher": "The Motley Fool", "title": "Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?", "image": "https://images.financialmodelingprep.com/news/can-abbvie-beat-pfizer-in-the-atopic-dermatitis-market-20220129.jpg", "site": "fool.com", "text": "Maybe. But neither is likely to knock Dupixent off its perch.", "url": "https://www.fool.com/investing/2022/01/29/can-abbvie-beat-pfizer-in-the-atopic-dermatitis-ma/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-29T05:58:00-05:00", "date_et": "2022-01-29"}
{"symbol": "ABBV", "publishedDate": "2022-01-29 07:00:00", "publisher": "Seeking Alpha", "title": "My Top Dividend Stocks For 2022", "image": "https://images.financialmodelingprep.com/news/my-top-dividend-stocks-for-2022-20220129.jpg", "site": "seekingalpha.com", "text": "My Top Dividend Stocks For 2022", "url": "https://seekingalpha.com/article/4482246-my-top-dividend-stocks-for-2022", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-29T07:00:00-05:00", "date_et": "2022-01-29"}
{"symbol": "ABBV", "publishedDate": "2022-01-30 11:28:00", "publisher": "The Motley Fool", "title": "Better Dividend Stock: AbbVie or Pfizer?", "image": "https://images.financialmodelingprep.com/news/better-dividend-stock-abbvie-or-pfizer-20220130.jpg", "site": "fool.com", "text": "One looks to have better growth prospects.", "url": "https://www.fool.com/investing/2022/01/30/better-dividend-stock-abbvie-or-pfizer/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-30T11:28:00-05:00", "date_et": "2022-01-30"}
{"symbol": "ABBV", "publishedDate": "2022-01-31 08:10:00", "publisher": "Seeking Alpha", "title": "'Blue Chip' You Cannot Afford To Miss, Yield 4.1%: AbbVie", "image": "https://images.financialmodelingprep.com/news/blue-chip-you-cannot-afford-to-miss-yield-41-20220131.jpg", "site": "seekingalpha.com", "text": "The upcoming loss of Humira exclusivity is a legitimate concern. However, robust sales of Rinvoq and Skyrizi are working to fill the gap.", "url": "https://seekingalpha.com/article/4482494-blue-chip-you-cannot-afford-to-miss-yield-4-1-percent-abbvie", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-31T08:10:00-05:00", "date_et": "2022-01-31"}
{"symbol": "ABBV", "publishedDate": "2022-01-31 12:20:09", "publisher": "Zacks Investment Research", "title": "AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery", "image": "https://images.financialmodelingprep.com/news/abbvies-abbv-q4-earnings-may-reflect-slower-sales-recovery-20220131.jpg", "site": "zacks.com", "text": "AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.", "url": "https://www.zacks.com/stock/news/1859943/abbvie-s-abbv-q4-earnings-may-reflect-slower-sales-recovery", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-31T12:20:09-05:00", "date_et": "2022-01-31"}
{"symbol": "ABBV", "publishedDate": "2022-01-31 13:27:31", "publisher": "24/7 Wall Street", "title": "Earnings Previews: AbbVie, Humana, Marathon Petroleum, Novartis", "image": "https://images.financialmodelingprep.com/news/earnings-previews-abbvie-humana-marathon-petroleum-novartis-20220131.jpg", "site": "247wallst.com", "text": "U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going.", "url": "https://247wallst.com/investing/2022/01/31/earnings-previews-abbvie-humana-marathon-petroleum-novartis/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-31T13:27:31-05:00", "date_et": "2022-01-31"}
{"symbol": "ABBV", "publishedDate": "2022-01-31 16:00:00", "publisher": "GlobeNewsWire", "title": "Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation", "image": "https://images.financialmodelingprep.com/news/inventiva-receives-a-4-million-milestone-payment-from-abbvie-20220131.jpg", "site": "globenewswire.com", "text": "Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the receipt of a €4 million milestone payment from AbbVie. It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157)1, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.", "url": "https://www.globenewswire.com/news-release/2022/01/31/2376097/0/en/Inventiva-receives-a-4-million-milestone-payment-from-AbbVie-for-cedirogant-Phase-IIb-initiation.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-31T16:00:00-05:00", "date_et": "2022-01-31"}
{"symbol": "ABBV", "publishedDate": "2022-01-31 16:48:21", "publisher": "GuruFocus", "title": "Analysts Think Sales of AbbVie's Migraine Drugs Will Each Top $2 Billion", "image": "https://images.financialmodelingprep.com/news/analysts-think-sales-of-abbvies-migraine-drugs-will-each-20220131.jpg", "site": "gurufocus.com", "text": "Two new migraine treatments from AbbVie Inc. ( ABBV , Financial) could help offset any headaches caused by declining sales of the company's mega-blockbuster Humira.", "url": "https://www.gurufocus.com/news/1629549/analysts-think-sales-of-abbvies-migraine-drugs-will-each-top-2-billion", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-01-31T16:48:21-05:00", "date_et": "2022-01-31"}
{"symbol": "ABBV", "publishedDate": "2022-02-01 00:02:43", "publisher": "Seeking Alpha", "title": "AbbVie Can Continue Generating Substantial Shareholder Returns", "image": "https://images.financialmodelingprep.com/news/abbvie-can-continue-generating-substantial-shareholder-returns-20220201.jpg", "site": "seekingalpha.com", "text": "AbbVie Can Continue Generating Substantial Shareholder Returns", "url": "https://seekingalpha.com/article/4483085-abbvie-can-continue-generating-substantial-shareholder-returns", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-01T00:02:43-05:00", "date_et": "2022-02-01"}
{"symbol": "ABBV", "publishedDate": "2022-02-01 08:45:00", "publisher": "PRNewsWire", "title": "AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO)", "image": "https://images.financialmodelingprep.com/news/abbvie-showcases-its-leadership-in-research-in-inflammatory-bowel-diseases-20220201.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., Feb. 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) at the 17th Congress of European Crohn's and Colitis Organisation (ECCO), to be held February 16-19.", "url": "https://www.prnewswire.com/news-releases/abbvie-showcases-its-leadership-in-research-in-inflammatory-bowel-diseases-with-new-analyses-to-be-presented-at-the-17th-congress-of-european-crohns-and-colitis-organization-ecco-301472617.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-01T08:45:00-05:00", "date_et": "2022-02-01"}
{"symbol": "ABBV", "publishedDate": "2022-02-01 09:59:25", "publisher": "Zacks Investment Research", "title": "Why AbbVie (ABBV) Might Surprise This Earnings Season", "image": "https://images.financialmodelingprep.com/news/why-abbvie-abbv-might-surprise-this-earnings-season-20220201.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "url": "https://www.zacks.com/stock/news/1860458/why-abbvie-abbv-might-surprise-this-earnings-season", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-01T09:59:25-05:00", "date_et": "2022-02-01"}
{"symbol": "ABBV", "publishedDate": "2022-02-01 11:30:21", "publisher": "Zacks Investment Research", "title": "Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO", "image": "https://images.financialmodelingprep.com/news/pharma-stocks-to-report-q4-earnings-on-feb-2-20220201.jpg", "site": "zacks.com", "text": "Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.", "url": "https://www.zacks.com/stock/news/1860564/pharma-stocks-to-report-q4-earnings-on-feb-2-abbv-nvs-nvo", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-01T11:30:21-05:00", "date_et": "2022-02-01"}
{"symbol": "ABBV", "publishedDate": "2022-02-01 11:45:00", "publisher": "The Motley Fool", "title": "Is AbbVie Stock a Buy Now?", "image": "https://images.financialmodelingprep.com/news/is-abbvie-stock-a-buy-now-20220201.jpg", "site": "fool.com", "text": "The pharma giant is tackling new competition for its blockbuster drug, but there remains more to do.", "url": "https://www.fool.com/investing/2022/02/01/is-abbvie-stock-a-buy-now/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-01T11:45:00-05:00", "date_et": "2022-02-01"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 07:43:00", "publisher": "PRNewsWire", "title": "AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results", "image": "https://images.financialmodelingprep.com/news/abbvie-reports-fullyear-and-fourthquarter-2021-financial-results-20220202.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., Feb. 2, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021.", "url": "https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results-301473737.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T07:43:00-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 07:46:00", "publisher": "Reuters", "title": "AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi", "image": "https://images.financialmodelingprep.com/news/abbvie-forecasts-2022-profit-above-estimates-on-strong-sales-20220202.jpg", "site": "reuters.com", "text": "AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-forecasts-2022-profit-above-estimates-strong-sales-botox-skyrizi-2022-02-02/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T07:46:00-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 08:06:52", "publisher": "Market Watch", "title": "AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humana", "image": "https://images.financialmodelingprep.com/news/abbvies-stock-gains-on-fourthquarter-earnings-as-it-reports-20220202.jpg", "site": "marketwatch.com", "text": "Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the company beat earnings expectations and generated more sales than expected of its top-selling rheumatoid arthritis drug, Humira. AbbVie had earnings of $4.0 billion, or $2.26 per share, in the fourth quarter of 2021, compared with $36.0 million, or 1 cent per share, in the same quarter a year ago.", "url": "https://www.marketwatch.com/story/abbvies-stock-gains-on-fourth-quarter-earnings-as-it-reports-better-than-expected-sales-of-humana-2022-02-02", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T08:06:52-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 10:34:41", "publisher": "Benzinga", "title": "AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings", "image": "https://images.financialmodelingprep.com/news/abbvie-expects-solid-fy22-as-botox-skyrizi-power-q4-20220202.jpg", "site": "benzinga.com", "text": "AbbVie Inc ABBV reports Q4 adjusted EPS of $3.31, higher than $2.92 reported a year ago and beating the consensus of $3.28. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.", "url": "https://www.benzinga.com/general/biotech/22/02/25366289/abbvie-expects-solid-fy22-as-botox-skyrizi-power-q4-earnings", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T10:34:41-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 10:46:22", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Tops Q4 Earnings Estimates", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-tops-q4-earnings-estimates-20220202.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://www.zacks.com/stock/news/1861235/abbvie-abbv-tops-q4-earnings-estimates", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T10:46:22-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 11:32:12", "publisher": "MarketBeat", "title": "High-Yield, Deep-Value AbbVie Confirms Uptrend", "image": "https://images.financialmodelingprep.com/news/highyield-deepvalue-abbvie-confirms-uptrend-20220202.jpg", "site": "marketbeat.com", "text": "Shares of AbbVie (NYSE: ABBV) fell in the wake of the Q4 results because the results were a little mixed in relation to the analyst's estimates. That dip resulted in a buy signal for the broader market, however, because mixed as they were, the results are strong, the outlook is positive, the dividend is safe, and AbbVie presents a deep value compared to the S&P 500.", "url": "https://www.marketbeat.com/originals/high-yield-deep-value-abbvie-confirms-uptrend/?SNAPI", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T11:32:12-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 12:21:54", "publisher": "CNBC", "title": "Cramer's Investing Club: We're encouraged AbbVie shares held recent gains after a mixed quarter", "image": "https://images.financialmodelingprep.com/news/cramers-investing-club-were-encouraged-abbvie-shares-held-recent-20220202.jpeg", "site": "cnbc.com", "text": "Despite some spotty results here and there, we saw strength in all the right places in AbbVie's fourth-quarter earnings report.", "url": "https://www.cnbc.com/2022/02/02/cramers-investing-club-were-encouraged-abbvie-shares-held-recent-gains-after-a-mixed-quarter.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T12:21:54-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 13:04:13", "publisher": "Zacks Investment Research", "title": "AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss", "image": "https://images.financialmodelingprep.com/news/abbvies-abbv-q4-earnings-surpass-estimates-sales-miss-20220202.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales.", "url": "https://www.zacks.com/stock/news/1861400/abbvie-s-abbv-q4-earnings-surpass-estimates-sales-miss", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T13:04:13-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 13:44:06", "publisher": "Seeking Alpha", "title": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2021 Results - Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/abbvie-inc-abbv-ceo-rick-gonzalez-on-q4-2021-20220202.jpg", "site": "seekingalpha.com", "text": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2021 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4483642-abbvie-inc-abbv-ceo-rick-gonzalez-on-q4-2021-results-earnings-call-transcript", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T13:44:06-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-02 15:14:04", "publisher": "Invezz", "title": "AbbVie tops fourth-quarter estimates by 3%", "image": "https://images.financialmodelingprep.com/news/abbvie-tops-fourthquarter-estimates-by-3-20220202.jpg", "site": "invezz.com", "text": "AbbVie (NYSE: ABBV) reports $3.31 EPS in the fourth quarter, which tops the $3.28 analyst estimate by $0.03. However, the company recorded $14.89 billion in revenue in the same quarter, a little less than the $14.95 billion consensus estimate.", "url": "https://invezz.com/news/2022/02/02/abbvie-tops-fourth-quarter-estimates-by-3/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-02T15:14:04-05:00", "date_et": "2022-02-02"}
{"symbol": "ABBV", "publishedDate": "2022-02-05 02:14:33", "publisher": "Seeking Alpha", "title": "SDOG: High Yield, Good Value, Questionable Quality", "image": "https://images.financialmodelingprep.com/news/sdog-high-yield-good-value-questionable-quality-20220205.jpg", "site": "seekingalpha.com", "text": "SDOG: High Yield, Good Value, Questionable Quality", "url": "https://seekingalpha.com/article/4484628-sdog-high-yield-good-value-questionable-quality", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-05T02:14:33-05:00", "date_et": "2022-02-05"}
{"symbol": "ABBV", "publishedDate": "2022-02-05 06:25:00", "publisher": "The Motley Fool", "title": "Is AbbVie Stock a Buy Now?", "image": "https://images.financialmodelingprep.com/news/is-abbvie-stock-a-buy-now-20220205.jpg", "site": "fool.com", "text": "The healthcare company just reported strong quarterly earnings.", "url": "https://www.fool.com/investing/2022/02/05/is-abbvie-stock-a-buy-now/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-05T06:25:00-05:00", "date_et": "2022-02-05"}
{"symbol": "ABBV", "publishedDate": "2022-02-05 08:35:00", "publisher": "Seeking Alpha", "title": "AbbVie Stock: Get In On This Investor Trifecta", "image": "https://images.financialmodelingprep.com/news/abbvie-stock-get-in-on-this-investor-trifecta-20220205.jpg", "site": "seekingalpha.com", "text": "AbbVie offers Growth Potential, High-Yield, and Strong Dividend Growth. The company has long been led by the #1 selling drug in the world in Humira, but they are now taking a more diversified approach.", "url": "https://seekingalpha.com/article/4484556-abbvie-stock-get-in-on-this-investor-trifecta", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-05T08:35:00-05:00", "date_et": "2022-02-05"}
{"symbol": "ABBV", "publishedDate": "2022-02-08 08:00:00", "publisher": "PRNewsWire", "title": "FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows", "image": "https://images.financialmodelingprep.com/news/fda-approves-juvderm-volbella-xc-for-undereye-hollows-20220208.jpg", "site": "prnewswire.com", "text": "IRVINE, Calif., Feb. 8, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the FDA approval of JUVÉDERM® VOLBELLA® XC for improvement of infraorbital hollows in adults over the age of 21.2 According to clinical trial data, 90% of subjects reported satisfaction through one year after treatment.2 With this approval, Allergan Aesthetics continues the expansion of its treatment portfolio to better address unmet patient needs.", "url": "https://www.prnewswire.com/news-releases/fda-approves-juvederm-volbella-xc-for-undereye-hollows-301477144.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-08T08:00:00-05:00", "date_et": "2022-02-08"}
{"symbol": "ABBV", "publishedDate": "2022-02-08 11:15:00", "publisher": "The Motley Fool", "title": "3 Top Healthcare Stocks to Buy for February", "image": "https://images.financialmodelingprep.com/news/3-top-healthcare-stocks-to-buy-for-february-20220208.jpg", "site": "fool.com", "text": "Whether you're looking for growth or big dividends, the healthcare sector's got deals galore.", "url": "https://www.fool.com/investing/2022/02/08/3-top-healthcare-stocks-to-buy-for-february/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-08T11:15:00-05:00", "date_et": "2022-02-08"}
{"symbol": "ABBV", "publishedDate": "2022-02-09 03:33:30", "publisher": "Pulse2", "title": "AbbVie (ABBV) Stock: Why The Price Increased", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-stock-why-the-price-increased-20220209.jpg", "site": "pulse2.com", "text": "The stock price of AbbVie Inc (NYSE: ABBV) increased by 0.69% in the most recent trading session. This is why it happened.", "url": "https://pulse2.com/abbvie-nyse-abbv-stock-why-the-price-increased/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-09T03:33:30-05:00", "date_et": "2022-02-09"}
{"symbol": "ABBV", "publishedDate": "2022-02-09 11:22:57", "publisher": "Seeking Alpha", "title": "AbbVie: Superb 2021 Paves Way For Further Outperformance In 2022", "image": "https://images.financialmodelingprep.com/news/abbvie-superb-2021-paves-way-for-further-outperformance-in-20220209.jpg", "site": "seekingalpha.com", "text": "AbbVie: Superb 2021 Paves Way For Further Outperformance In 2022", "url": "https://seekingalpha.com/article/4485480-abbvie-superb-2021-paves-way-for-further-outperformance-in-2022", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-09T11:22:57-05:00", "date_et": "2022-02-09"}
{"symbol": "ABBV", "publishedDate": "2022-02-10 09:00:00", "publisher": "PRNewsWire", "title": "Healis Therapeutics acquires ownership of key botulinum toxin patent", "image": "https://images.financialmodelingprep.com/news/healis-therapeutics-acquires-ownership-of-key-botulinum-toxin-patent-20220210.jpg", "site": "prnewswire.com", "text": "WASHINGTON, Feb. 10, 2022 /PRNewswire/ -- Healis Therapeutics, a privately held biotechnology company, today announces its ownership of a key botulinum toxin patent from AbbVie (NYSE: ABBV). After clinically significant results in early trials, Allergan acquired the rights to develop botulinum toxin for depression in 2013.", "url": "https://www.prnewswire.com/news-releases/healis-therapeutics-acquires-ownership-of-key-botulinum-toxin-patent-301479416.html", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-10T09:00:00-05:00", "date_et": "2022-02-10"}
{"symbol": "ABBV", "publishedDate": "2022-02-11 05:29:00", "publisher": "The Motley Fool", "title": "2 Dividend Stocks That Are Better Investments Than AT&T", "image": "https://images.financialmodelingprep.com/news/2-dividend-stocks-that-are-better-investments-than-att-20220211.jpg", "site": "fool.com", "text": "Not only do they pay high yields, they also have plenty of growth opportunities on the horizon.", "url": "https://www.fool.com/investing/2022/02/11/2-dividend-stocks-that-are-better-investments-than/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-11T05:29:00-05:00", "date_et": "2022-02-11"}
{"symbol": "ABBV", "publishedDate": "2022-02-11 07:33:09", "publisher": "Seeking Alpha", "title": "AbbVie: Portfolio Topper - Try It You'll Like It", "image": "https://images.financialmodelingprep.com/news/abbvie-portfolio-topper-try-it-youll-like-it-20220211.jpg", "site": "seekingalpha.com", "text": "AbbVie routinely meets and slightly beats ambitious growth targets, as it demonstrated again in its Q4, 2021 earnings call.", "url": "https://seekingalpha.com/article/4486268-abbvie-portfolio-topper-try-it-youll-like-it", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-11T07:33:09-05:00", "date_et": "2022-02-11"}
{"symbol": "ABBV", "publishedDate": "2022-02-11 12:19:11", "publisher": "Zacks Investment Research", "title": "Will the Rally of These 5 Big Drugmakers Continue in 2022?", "image": "https://images.financialmodelingprep.com/news/will-the-rally-of-these-5-big-drugmakers-continue-20220211.jpg", "site": "zacks.com", "text": "Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.", "url": "https://www.zacks.com/stock/news/1866486/will-the-rally-of-these-5-big-drugmakers-continue-in-2022", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-11T12:19:11-05:00", "date_et": "2022-02-11"}
{"symbol": "ABBV", "publishedDate": "2022-02-14 14:29:44", "publisher": "InvestorPlace", "title": "7 Dividend Aristocrats That Could Outpace This Volatile Market", "image": "https://images.financialmodelingprep.com/news/7-dividend-aristocrats-that-could-outpace-this-volatile-market-20220214.jpg", "site": "investorplace.com", "text": "Dividend aristocrats are companies that have raised dividend payments at least once a year for the past 25 years. The post 7 Dividend Aristocrats That Could Outpace This Volatile Market appeared first on InvestorPlace.", "url": "https://investorplace.com/2022/02/7-dividend-aristocrats-that-could-outpace-this-volatile-market/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-14T14:29:44-05:00", "date_et": "2022-02-14"}
{"symbol": "ABBV", "publishedDate": "2022-02-14 16:23:15", "publisher": "InvestorPlace", "title": "4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR", "image": "https://images.financialmodelingprep.com/news/4-top-stock-trades-for-tuesday-se-abbv-td-20220214.jpg", "site": "investorplace.com", "text": "Sea Ltd, AbbVie, Toronto Dominion Bank and Avis Budget were our top stock trades for Tuesday. Here's how the charts look now.", "url": "https://investorplace.com/2022/02/4-top-stock-trades-for-tuesday-se-abbv-td-car/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-14T16:23:15-05:00", "date_et": "2022-02-14"}
{"symbol": "ABBV", "publishedDate": "2022-02-14 19:39:03", "publisher": "Kiplinger", "title": "10 Stocks Warren Buffett Is Selling", "image": "https://images.financialmodelingprep.com/news/10-stocks-warren-buffett-is-selling-20220214.jpg", "site": "kiplinger.com", "text": "Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.", "url": "https://www.kiplinger.com/investing/stocks/604219/stocks-warren-buffett-is-buying-and-selling-q4-2021", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-14T19:39:03-05:00", "date_et": "2022-02-14"}
{"symbol": "ABBV", "publishedDate": "2022-02-15 10:55:44", "publisher": "Seeking Alpha", "title": "Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB", "image": "https://images.financialmodelingprep.com/news/which-etfs-should-investors-be-watching-now-our-favorite-20220215.jpg", "site": "seekingalpha.com", "text": "Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB", "url": "https://seekingalpha.com/article/4487076-which-etfs-should-investors-be-watching-now-favorite-ibb", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-15T10:55:44-05:00", "date_et": "2022-02-15"}
{"symbol": "ABBV", "publishedDate": "2022-02-15 13:12:44", "publisher": "GuruFocus", "title": "Buffett Still Likes Chevron, Continues to Sell Health Care", "image": "https://images.financialmodelingprep.com/news/buffett-still-likes-chevron-continues-to-sell-health-care-20220215.jpg", "site": "gurufocus.com", "text": "Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its fourth-quarter 13F on Monday.", "url": "https://www.gurufocus.com/news/1642988/buffett-still-likes-chevron-continues-to-sell-health-care", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-15T13:12:44-05:00", "date_et": "2022-02-15"}
{"symbol": "ABBV", "publishedDate": "2022-02-16 07:30:00", "publisher": "The Motley Fool", "title": "Why Abbvie Might Be Poised for a Return to Profitability", "image": "https://images.financialmodelingprep.com/news/why-abbvie-might-be-poised-for-a-return-to-20220216.jpg", "site": "fool.com", "text": "Is now an optimal time to buy?", "url": "https://www.fool.com/investing/2022/02/16/why-abbvie-might-be-poised-for-a-return-to-profita/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-16T07:30:00-05:00", "date_et": "2022-02-16"}
{"symbol": "ABBV", "publishedDate": "2022-02-16 10:00:00", "publisher": "The Motley Fool", "title": "2 Warren Buffett Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/2-warren-buffett-stocks-to-buy-and-hold-forever-20220216.jpg", "site": "fool.com", "text": "The Oracle of Omaha has historically beaten the market, so it might not be a bad thing to pick up a few tips from him.", "url": "https://www.fool.com/investing/2022/02/16/2-warren-buffett-stocks-to-buy-and-hold-forever/", "ticker": "ABBV", "event_date": "2022-02-02", "window_start": "2022-01-19", "window_end": "2022-02-16", "publishedDateET": "2022-02-16T10:00:00-05:00", "date_et": "2022-02-16"}
